Onyx Biotec Ltd. was incorporated on May 13, 2005. The company is a key player in the healthcare sector, supplying sterile pharmaceutical products to major corporations, including top pharma companies across India. The company manufactures Sterile Water for Injections and offers contract manufacturing services for dry powder injections and dry syrup, both domestically and internationally, while maintaining a commitment to high-quality products at affordable prices
| Bidding Dates |
|---|
| 13 Nov 2024 - 18 Nov 2024 |
| Subscription |
|---|
| 184.6x Oversubscribed |
| Minimum Investment | Minimum Lot | Maximum Lot | Lot Size | Number of Shares | Issue Price Band | Post Issue Promoter Holding % | Issue Size | IPO Document |
|---|---|---|---|---|---|---|---|---|
| ₹1,16,000 | 1 | 1 | 2000 | 4.8 M | ₹58 - ₹61 | 65.1 % | ₹279.0 M - ₹293.4 M | RHP DOC |
Onyx Biotec Ltd. IPO SUBSCRIPTION STATUS
18 Nov '24Onyx Biotec Ltd. IPO overall subscription rate was 184.6 times the total available shares
Onyx Biotec Ltd. IPO retail subscription rate was 158.25 times in the retail segment
Onyx Biotec Ltd. IPO non-institutional investor subscription rate was 799.92 times in the non-institutional investor category
Onyx Biotec Ltd. IPO Qualified Institutional Bidder subscription rate was 17.25 times the available shares for Qualified Institutional Bidder
| Day | Retail Individual Investor | HNI (NII) Investors | Qualified Institutional Buyers |
|---|---|---|---|
| Category Reservation | 35.04% | 15.07% | 49.89% |
18 Nov 2024 (Day 3) | 158.25x | 799.92x | 17.25x |
14 Nov 2024 (Day 2) | 21.19x | 11.19x | - |
13 Nov 2024 (Day 1) | 7.06x | 2.18x | - |
Onyx Biotec Ltd. FINANCIALS
| Period | Net Profit (Rs in millions) | Revenue from Operations (Rs in millions) | Cash Flow from Operations (Rs in millions) | Free Cash Flow (Rs in millions) | Margins |
| 2MFY25 | 13.1 | 105.3 | -11.9 | -12.2 | 26.0% |
| FY24 | 30.3 | 537.5 | 15.2 | -17.1 | 15.4% |
| FY23 | 18.4 | 394.8 | 62.4 | 30.1 | 11.3% |
| FY22 | 33.5 | 448.6 | 4.9 | -53.0 | 12.6% |
Onyx Biotec Ltd. IPO SUBSCRIPTION STATUS DETAILS
Onyx Biotec Ltd. had 4.8 M shares on offer
Onyx Biotec Ltd. IPO offer price was in the range ₹58 - ₹61
Onyx Biotec Ltd. IPO minimum Investment was ₹116000
Onyx Biotec Ltd. IPO issue size was ₹ 279.0 M - ₹ 293.4 M
Onyx Biotec Ltd. had a minimum lot size of 2000 Shares per application
Onyx Biotec Ltd. NUMBER OF SHARES ON OFFER
Onyx Biotec Ltd. IPO IMPORTANT DATES
| Issue Open Date | 13 Nov 2024 |
| Issue close Date | 18 Nov 2024 |
| Allotment Date | 19 Nov 2024 |
| Refund Date | 20 Nov 2024 |
| Demat Account Credit Date | 20 Nov 2024 |
| Listing Date | 22 Nov 2024 |
| Listing on Exchange(s) | NSE |
| Onyx Biotec Ltd. Allotment Status | Exchange |
Onyx Biotec Ltd. IPO subscription opened on 13 Nov 2024, and closed on 18 Nov 2024
IPO allotment for Onyx Biotec Ltd. was finalized on Tuesday, 19 Nov 2024
IPO listing for Onyx Biotec Ltd. was on NSE on Friday, 22 Nov 2024
Onyx Biotec Ltd. IPO LISTING GAINS
| Issue Price (adjusted) | 61.0 |
| Listing Open Price | 54.0 |
| Listing Close Price | 56.8 |
| Listing Gain% | -11.4% |
| Current Gain% | -25.6% |
Onyx Biotec Ltd. Peer
| Stock | Stock Price | Market Cap (Rs crore) | PE TTM | PEG TTM | PS TTM | ROE% | ROA% | Annual Revenue (Rs crore) | Annual Revenue Growth % | Annual Net Profit (Rs crore) | Annual Net Profit Growth % | EPS TTM | EPS TTM Growth % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Onyx Biotec Ltd. | 45.4 | 82.3 | -384 | 3.7 | 1.2 | -0.4 | -0.2 | 69.9 | 10.8 | -0.2 | -104.3 | -0.1 | -104.3 |
| Sun Pharmaceutical Industries Ltd. | 1945 | 466670.7 | 38.6 | 2.3 | 7.8 | 13.7 | 10.6 | 60433.8 | 10.8 | 11479.4 | 5 | 50.4 | 16.6 |
| Divi's Laboratories Ltd. | 8275 | 219675.3 | 75.1 | 2.8 | 19.6 | 15.3 | 12.8 | 11067 | 14 | 2568 | 17.2 | 110.2 | 26.8 |
| Torrent Pharmaceuticals Ltd. | 4924 | 187293.2 | 85.9 | 9.6 | 11.9 | 25.8 | 4.9 | 13886.2 | 20.3 | 2163.4 | 13.2 | 57.3 | 8.9 |
| Cipla Ltd. | 1463.8 | 118253.6 | 35.1 | -0.9 | 4.2 | 11.3 | 9.1 | 29044.6 | 2.2 | 3879.2 | -26.4 | 41.7 | -37.5 |
| Zydus Lifesciences Ltd. | 1114.2 | 112114.6 | 22.2 | 2.3 | 4.1 | 18.6 | 9.6 | 27657.9 | 17.6 | 5040 | 11.4 | 50.1 | 9.6 |
Onyx Biotec Ltd. INFORMATION ON IPO ISSUE
About Onyx Biotec Ltd.
Onyx Biotec Ltd. was incorporated on May 13, 2005. The company is a key player in the healthcare sector, supplying sterile pharmaceutical products to major corporations, including top pharma companies across India. The company manufactures Sterile Water for Injections and offers contract manufacturing services for dry powder injections and dry syrup, both domestically and internationally, while maintaining a commitment to high-quality products at affordable prices
Object of the Issue
- Upgradation of existing manufacturing unit I to manufacture large volume parentals for intravenous use
- Setting up a high-speed cartooning packaging line at existing manufacturing unit II for dry powder injections
- Prepayment or repayment of all or a portion of certain loans availed by the company
- General corporate purposes
Onyx Biotec Ltd. - PROMOTERS
| Name |
|---|
| Sanjay Jain |
| Naresh Kumar |
| Fateh Pal Singh |
| Harsh Mahajan |
| Lakshya Jain |
| Parmjeet Kaur |
Onyx Biotec Ltd. Lead Manager of the Issue
Horizon Management Private Limited
smeipo@horizon.net.co
Onyx Biotec Ltd. Registrar to the issue
MAS Services Limited
ipo@masserv.com
Onyx Biotec Ltd. Strengths
Prominent contract manufacturers
With a strong brand and reputation built over a decade, Onyx is well-positioned to expand its clientele in the future. Despite challenges in the pharmaceutical industry, such as high capital costs, quality control demands, skilled labor requirements, and lengthy regulatory processes, the company has established itself as a leader in sterile manufacturing
Geographical presence
The company offers its products across multiple regions, with its registered office and manufacturing units in Solan, Himachal Pradesh, a key pharmaceutical hub in India. The company also operates its corporate and marketing office in Chandigarh
Quality assurance and control
The company meets customer demands for rigorous quality checks by employing experienced chemists and microbiologists in manufacturing and quality control. Dedicated teams ensure thorough inspections, preventing rejections and maintaining the highest quality standards
Onyx Biotec Ltd. Risks
Dependent on manufacturing plant
The company's manufacturing units are located in Solan, Himachal Pradesh, exposing it to risks from economic, regulatory, political, and environmental changes in the region, which could impact its operations and financial condition
Quality control
Manufacturing or quality control issues, or failure to deliver products on time, could lead to order cancellations, contract breaches, and terminations, negatively affecting the company's business, operations, financial condition, and cash flow
Periodic inspections and audits
The company's manufacturing units undergo periodic inspections by regulatory authorities and clients. Any regulatory action could harm its reputation, negatively affecting business, operations, financial condition, and cash flow
IPO FAQs
The promoters of the company are Sanjay Jain, Naresh Kumar, Fateh Pal Singh, Harsh Mahajan, Lakshya Jain and Parmjeet Kaur.
The category allocation of qualified institutional buyers is 49.9%, the category allocation of non individual investors or high networth individuals is 15.1% and for retail investors it is 35.0%.
The price band of the IPO is Rs 58.0 - 61.0.
The IPO application opens on Nov 13, 2024 and closes on Nov 18, 2024.
The minimum lot size for the IPO is 2000. The maximum lot size for the IPO is 2000.
For all category investors, the minimum application amount for this IPO is Rs. 116,000.0, the maximum value for this IPO is Rs 122,000.0.
This IPO will be allotted on Nov 19, 2024.
The refund will be credited to your account on Nov 20, 2024.
The allotted shares will be credited to your demat on Nov 20, 2024.
Onyx Biotec Ltd.’s shares listed on the stock exchanges on Nov 22, 2024.